Search Results 451-460 of 18372 for alopecia

1. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer - Mayo Clinic

   toxicities related to prior therapies (i.e. prior chemotherapy, radiation, etc.) except alopecia 11. Participants must have adequate organ function: - Bone ...

2. A Study of ASTX660 Alone or Combined with ASTX727 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) - Mayo Clinic

   ... alopecia). Hypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients. Liver cirrhosis, or chronic liver disease Child-Pugh Class B or C ...

3. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy. Subjects with treated brain metastases with ...

4. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

   Patients with any grade of alopecia are allowed to enter the study. Patients must have adequate organ function; ECOG performance status (PS) of 0 or 1 ...

5. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not ...

6. Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer - Mayo Clinic

   Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for ...

7. KO-2806 Monotherapy And Combination Therapies In Advanced Solid Tumors - Mayo Clinic

   * Toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent. * Active or prior documented ...

8. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

   recovered from adverse events (other than alopecia or neuropathy) due to agents administered more than 4 weeks earlier. However, the following therapies are ...

9. An Expanded Access Study of Iniparib Combined with Gemcitabine and Carboplatin for the Treatment of Breast Cancer - Mayo Clinic

   ... alopecia, related to anticancer therapy prior to the first dose of study drug; Major medical conditions that might affect EAP participation (e.g. ...

10. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    ... alopecia), or deemed irreversible from the effects of prior cancer therapy; Major surgery, serious infection, or infection requiring systemic antibiotic ...